In this aim, we made use of neurofilament light chain (NfL) levels in plasma and serum of patients, a relevant biomarker for axonal injury in neurological diseases, quantified by an ultrasensitive single-molecule array (Simoa) assay recently developed.15 The gene discussed is NEFL; the disease is nervous system disorder.